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Accepted 24 June 2019Managing type 2 diabetes is complex and necessitates careful consideration of patient factors such as engage-
ment in self-care, comorbidities and costs. Since type 2 diabetes is a progressive disease, many patients will re-
quire injectable agents, usually insulin. Recent ADA-EASD guidelines recommend glucagon-like peptide 1
receptor agonists (GLP-1 RAs) as first injectable therapy in most cases. The basis for this recommendation is
the similar glycemic efficacy of GLP-1 RAs and insulin, but with GLP-1 RAs promoting weight loss instead of
weight gain, at lower hypoglycemia risk, and with cardiovascular benefits in patients with pre-existing cardio-
vascular disease. GLP-1 RAs also reduce burden of glucose self-monitoring. However, tolerability and costs are
important considerations, and notably, rates of drug discontinuation are often higher for GLP-1 RAs than basal
insulin. To minimize risk of gastrointestinal symptoms patients should be started on lowest doses of GLP-1 RAs
and up-titrated slowly. Overall healthcare costs may be lower with GLP-1 RAs compared to insulin. Though
patient-level costs may still be prohibitive, GLP-1 RAs can replace 50–80 units of insulin daily and reduce costs
associated with glucose self-monitoring. Decisions regarding initiating injectable therapy should be individual-
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Management of type 2 diabetes is complex, and quality care necessi-
tates careful consideration of patient factors such as preferences,
engagement in self-care, comorbidities and costs. Goals of diabetes care
include preventing diabetes-related complications and maintaining or
enhancing quality of life. Since type 2 diabetes is a progressive disease,
achieving these goals will often require intensification to injectable ther-
apy. Classically this has been accomplished with insulin. One in four pa-
tients will require insulin within 6 years of starting oral glucose-
lowering therapies [1,2]. In the United States, insulin was the only inject-
able option for diabetes until 2005, when exenatide, a glucagon-like pep-
tide 1 receptor agonist (GLP-1 RA), was approved for use by the Food and
Drug Association (FDA). Since then, five additional GLP-1 RAs have been
approved for use: lixisenatide, albiglutide, dulaglutide, liraglutide and
semaglutide; though albiglutide was withdrawn from the market in
2018. These agents can be broadly characterized as xenopeptides
(exenatide and lixisenatide), human GLP-1 analogs (liraglutide and
semaglutide), and fusion peptides (albiglutide and dulaglutide). The
xenopeptides are short-acting, though exenatide is also available in a
long-acting weekly formulation. Liraglutide administered once daily and
the four once-weekly formulations (albiglutide, dulaglutide, weekly
exenatide, and semaglutide) provide longer durations of action. Mean-
while, insulin options have also expanded to include human insulins,
multiple rapid- and long-acting insulin analogs, concentrated formula-
tions and premixes. With an expanding armamentarium of injectable
glucose-lowering agents, it is important for providers and patients to
weigh risks and benefits of each option and to examine patient factors
which may guide the choice of one agent over another.
The 2018 American Diabetes Association and the European Associa-
tion for the study of Diabetes (ADA-EASD) consensus statement on the
management of type 2 diabetes recognized GLP-1 RAs as first-line in-
jectable therapy before basal insulin, except when 1) hemoglobin A1c
(HbA1c) is N11%, 2) there is evidence of catabolism, such as weight
loss, polyuria and polydipsia, or 3) there is concern that a patient may
have type 1 or pancreatogenic diabetes [3]. GLP-1 RAs emerged in pref-
erence to insulin as initial injectable therapy because of comparable ef-
ficacy but with weight loss instead of weight gain, less hypoglycemia,
and in the setting of cardiovascular disease, benefits on myocardial in-
farction, stroke and cardiovascular death [3]. However, in many cases,
rates of drug discontinuation are higher with GLP-1 RAs than with
basal insulin [4,5]. In this article we explore issues related to injectable
glucose-lowering therapies, and provide readers with a guide to using
them in everyday clinical practice.
2. Glycemic efficacy of injectable agents in diabetes
2.1. GLP-1 receptor agonists versus basal insulin
GLP-1 receptor agonists induce glucose-dependent insulin secretion,
suppress glucagon secretion, slow gastric emptying and enhance satiety
[6]. Evidence suggests that glycemic efficacy is greatest for semaglutide
once-weekly, followed in descending order by dulaglutide, liraglutide,
exenatide, albiglutide and lixisenatide [3,7]. Multiple studies have com-
pared the efficacy of GLP-1 RAs versus basal insulins glargine, detemir
and degludec in patients inadequately controlled on oral glucose-
lowering therapies (Table 1) [8,9]. In general, the glycemic efficacy of
long-acting GLP-1 RAs has been greater than basal insulin. For instance,
in a head-to-head trial of semaglutide once-weekly versus glargine
once-daily [10], change from baseline HbA1c with semaglutide was dou-
ble that observed with glargine. Even in studies that have compared glu-
cose lowering in patients with HbA1c up to 11%, the equivalent or greater
efficacy of GLP-1 RAs to basal insulin has been clearly demonstrated [9].
2.2. GLP-1 receptor agonist versus prandial insulin
GLP-1 RAs have the ability to reduce fasting and post-prandial hyper-
glycemia. The short-acting GLP-1 RAs (exenatide twice-daily and
lixisenatide) have considerable post-prandial efficacy at the meals con-
sumed immediately after injection, but little fasting efficacy. The long-acting GLP-1 RAs exhibit greater impact on fasting glucose levels
[11,12]. Therefore, in addition to exploring GLP-1 RAs as alternatives to
basal insulin, they have been examined in comparison to prandial and
premixed insulins (Table 2), both in the presence and absence of basal in-
sulin therapy. In both cases, GLP-1 RAs appear to have similar efficacy as
insulin. As such, GLP-1 RAs are effective as alternatives to rapid-acting in-
sulins, although prandial insulin alone is rarely prescribed as first inject-
able therapy in practice.
2.3. Combining GLP-1 receptor agonists and insulin
While stepwise addition of glucose-lowering agents is generally pre-
ferred over initial combination therapy, the latter can be considered
when patients present with HbA1c levels well above target (i.e. ≥1.5%)
[3]. In 2016 the FDA approved two combination products with fixed ra-
tios of GLP-1 RA and basal insulin: insulin degludec plus liraglutide [13]
and insulin glargine plus lixisenatide [14]. These fixed-dose combina-
tion products appear to be more effective at lowering HbA1c as com-
pared to escalation of basal insulin alone (difference −0.53%, 95% CI
−0.66, −0.40, p-value b0.001), with equivalent hypoglycemia risk
and less weight gain [15]. Thus, fixed-dose GLP-1 RA/basal insulin for-
mulations can be considered as first injectable therapy in select patients
with uncontrolled diabetes, however it is important to considermedica-
tion costs and less flexibility of dosing when opting for this approach.
2.4. Glycemic efficacy versus effectiveness
While the efficacy of GLP-1 RA therapy and insulin appear similar in
randomized controlled trials (RCTs), it is worthwhile noting that patients
enrolled in RCTs are highly selected individuals who are likelymoremoti-
vated, adherent, and supported, thus are not reflective of populations en-
countered in practice. As such, the effectiveness of glucose-lowering
agents in real-world settings varies substantially to the efficacy noted in
RCTs [4]. A recent study compared the efficacy of GLP-1 RAs (exenatide,
liraglutide) between RCTs and administrative claims data (linked to elec-
tronic health records), and found a mean change in HbA1c of −1.30% in
RCTs, versus only −0.52% in real-world data [16]. Lack of adherence
accounted for 75% of this discrepancy [16]. Persistence rates in real-
world settings vary depending on the study, though rates generally de-
crease with longer study duration [4]. Factors influencing adherence and
persistence to GLP-1 RA therapy are likely similar, including cost consider-
ations, side effects, convenience of dosing and administration, as well as
marketplace issues such as safety concerns advertised by lawyers and
changing coverage patterns of various health plans. Of note, even in the
context RCTs comparing once-daily GLP-1 RA (liraglutide) to once-daily
basal insulin, discontinuation rates for GLP-1 RA were higher [17]. This
suggests that side effects of GLP-1 RAs are at least in part responsible for
lack of persistence to therapy, since administration is similar between
once-daily liraglutide and basal insulin, and cost issues are unlikely to un-
derlie medication discontinuation in the context of an RCT. In terms of
predicting patterns of adherence and persistence, a recent study by
Durden et al. [18] found that patients were more likely to adhere to GLP-
1 RA therapy over an 18 month period if they experienced an HbA1c re-
duction of N1% (OR 1.59, 95% CI 1.36, 1.85) or body weight reduction of
N3%(OR1.18, 95%CI 1.02, 1.36)within 3–6months of drug initiation, com-
pared to those without an early response. These early responders also had
significantly lower likelihood of discontinuation compared to patients
without early response (HbA1c reduction b1%: OR 0.62, 95% CI 0.53,
0.72; weight reduction b3%: OR 0.81, 95% CI 0.70, 0.94) [18].
Though theoretically insulin has limitless glycemic efficacy, in practice, its
titration is limited by hypoglycemia and/or fear of hypoglycemia (Table 3).
2.4.1. Weight effects
A major advantage of GLP-1 RA therapy over insulin is its ability to
promote satiety and clinicallymeaningful weight reduction, while insu-
lin treatment is often associated with weight gain. This is exceedingly
Table 1










Davies et al. [61]
(HEELA)
Met, SU, TZD 26 weeks Exenatide 5–10 μg BID −1.3 −2.7*** 50% (11.9%a)
Glargine qD −1.3 +3.0 59.6% (29.8%a)
Diamant et al. [62]
(DURATION-3)
Met ± SU 26 weeks Exenatide 2 mg qW −1.5* −2.6*** 8%
Glargine qD −1.3 +1.4 26%
Diamant et al. [63]
(DURATION-3
extension)
Met ± SU 84 weeks Exenatide 2 mg weekly −1.2* −2.1*** 24% if on SU, 8% if on Met
Glargine qD −1.0 +2.4 54% if on SU
32% if on Met
Diamant et al. [64]
(DURATION-3
extension)
Met ± SU 156 weeks Exenatide 2 mg weekly −1.0* −2.5*** 0.3 events/pt/yr
Glargine qD −0.8 +2.0 0.9 events/pt/yr
Heine et al. [65] Met, SU 26 weeks Exenatide 5–10 μg BID −1.1 −2.3 7.3 events/pt/yr (0.9a)
Glargine qD −1.1 +1.8 6.3 events/pt/yr
(2.4a)
Inagaki et al. [66] Met ± TZD 26 weeks Exenatide 5–10 μg BID −1.1*** −1.7*** 9.3% (0.9%a)
Glargine qD −0.7 +0.3 12.3% (10.4%a)
Araki et al. [67] Met ± SU 26 weeks Dulaglutide 0.75 mg qW −1.4*** −0.50*** 26%
Glargine qD −0.9 +0.9 48%
Blonde et al. [68]
(AWARD-4)





Glargine qD −1.4 +2.3 5.1%
D'Alessio et al. [17]
(EAGLE)
Met ± SU 24 weeks Liraglutide 0.6–1.8 mg qD −1.8 −3.0*** 18%
Glargine qD −1.9* +2.0 45%
Giorgino et al. [69]
(AWARD-2)






Glargine qD −0.6 +1.4 69.1%
Russell-Jones et al. [70]
(LEAD-5)
Met, SU 26 weeks Liraglutide 1.8 mg qD −1.3** −1.8*** 2.3 events/pt/yr
Glargine qD −1.1 +1.6 3.1 events/pt/yr
Davies et al. [71] Met ± SU 26 weeks Exenatide 2 mg weekly −1.3*** −2.7*** 6%
Detemir qD or BID −0.9 +0.8 7%
Gough et al. [72]
(DUAL-I)
Met ± TZD 26 weeks Liraglutide 0.6–1.8 mg qD −1.3 −3.0 0.2 events/pt/yr
Degludec qD −1.4 +1.6 2.6 events/pt/yr
Gough et al. [73]
(DUAL-I extension)
Met ± TZD 52 weeks Liraglutide 0.6–1.8 mg qD −1.2 −3.0 1.9 events/pt/yr
Degludec qD −1.4 +2.3 2.8 events/pt/yr
Weissman et al. [74]
(HARMONY-4)
Met ± SU 52 weeks Albiglutide 30–50 mg qW −0.7 −1.1*** 17.5%
Glargine qD −0.8 +1.6 27.4%
Aroda et al. [10]
(SUSTAIN-4)






Glargine qD −0.8 +1.15 11%b
This table includes only randomized controlled trials of ≥24 weeks duration comparing GLP-1 RA versus basal insulin. Abbreviations: Δ = change in; HbA1c = hemoglobin A1c; TID =
three times daily; BID = twice daily; qD = daily; qW = weekly; Met = metformin; SU = sulfonylurea; TZD = thiazolidinedione; IDeg = insulin degludec; IGlar = insulin glargine;
events/pt/yr = events per patient per year. Statistical significance for HbA1c and weight changes: * = p-value b0.05, ** = p-valueb0.01, *** = p-value b0.001.
a Nocturnal hypoglycemia.
b Severe or documented hypoglycemia, otherwise all hypoglycemia rates are minor or overall reported daytime hypoglycemia.
Table 2





Treatment Δ HbA1c during
study
Δ Weight (kg) during
study
Rate of hypoglycemia
Bergenstal et al. [75] Met, SU 24 weeks Exenatide 5–10 μg BID −1.8 −1.9 29%





Gallwitz et al. [76] Met 26 weeks Exenatide 5–10 μg BID −1.0 −4.1*** 8.0%
Premixed aspart 70/30 −1.1 +1.0 20.5%
Nauck et al. [77] SU 52 weeks Exenatide 5–10 μg BID −1.0 −2.5*** 17%a
Premixed aspart 70.30 −0.9 +2.9 25%a
Matthieu et al. [78]
(BEGIN VICTOZA ADD-ON)
iDeg, Met 26 weeks Liraglutide 0.6–1.8 mg qD −0.7** −2.8*** 86% lower rate in liraglutide arm
Aspart qD −0.4 +0.9
Rosenstock et al. [79]
(HARMONY-6)
iGlar ± Met ± TZD 36 weeks Albiglutide 30–50 mg qW −0.8 −0.7*** 15.8%
Lispro TID −0.7 +0.8 29.9%
Diamant et al. [80] Met, iGlar 30 weeks Exenatide 5–10 μg BID −1.1 −2.5*** 15% (25%a)
Lispro TID −1.1 +2.1 34% (27%a)
Xu et al. [81]
(CONFIDENCE)
None 48 weeks Exenatide 5–10 μg BID −1.8 −3.5*** 9.2%
Premixed lispro 75/25 −1.7 +1.0 13.0%
Rosenstock et al. [82] iGlar ± Met 26 weeks Lixisenatide 10 ➔ 20 μg qD −0.6 −0.6*** 35.9%
Glulisine TID TID: −0.8 TID: +1.4 TID: 52.4%
This table includes only randomized controlled trials of ≥24weeks duration comparingGLP-1 RA versus prandial or premixed insulin. Abbreviations:Δ=change in; HbA1c=hemoglobin
A1c; TID = three times daily; BID = twice daily; qD = daily; qW=weekly; Met =metformin; SU= sulfonylurea; TZD = thiazolidinedione; IDeg = insulin degludec; IGlar = insulin
glargine. Statistical significance for HbA1c and weight changes: * = p-value b0.05, ** = p-valueb0.01, *** = p-value b0.001.
a Nocturnal hypoglycemia.
Table 3
Comparison of glucagon-like 1 peptide receptor agonists and insulin.
Insulin GLP-1 Receptor agonists
Glycemic
efficacy
Very effective Very effective at full doses
Weight Weight gain Weight loss
Hypoglycemia Yes No, but increases hypoglycemic




Neutral Benefit in patients with pre-existing
atherosclerotic cardiovascular
disease
Administration 1–4 injections daily
Vial/syringe or pens





Not necessary unless combined with











Hypoglycemia Gallstone events, but does not
translate to increase in
gallstone-associated pancreatitis
Cost Cost of insulin analogues
has been increasing
dramatically
Cost-effective for healthcare systems
Cost may be comparable to insulin
analogues, but more expensive than
human insulins
Remain cost prohibitive for some
patientsimportant when considering the negative impact of adiposity on glyce-
mic control, and the vicious cycle generated when medication-induced
weight gain drives further need for diabetes regimen intensification.
Additionally, weight gain from insulin occurs not only at first initiation,
but also cumulatively with escalating insulin doses over time [19]. Con-
current initiation of basal insulin and GLP-1 RA can offset weight gain
due to insulin, and combination formulations have even demonstrated
reductions in weight [20,21].
Weight loss from GLP-1 RAs ranges from 1.5 kg to 6.0 kg over
30 weeks in clinical trials settings [7,22]. Evidence suggests that weight
loss efficacy is greatest for semaglutide once weekly (mean 4.11 kg ver-
sus placebo), followed in descending order by liraglutide, dulaglutide,
exenatide, albiglutide and lixisenatide [7,22]. In contrast, insulin leads
to weight gain of 3 to 9 kg within the first year of initiation [19].
While obese patients are traditionally considered at highest risk of fur-
ther weight gain and its consequences [19], real-world data suggests
that patients with normal body mass index (BMI) experience more rel-
ative weight gain when starting insulin compared to obese patients
[23]. This is noteworthy since there is a tendency to prescribe basal in-
sulin over GLP-1 RA as a first injectable for patients with normal BMI
[24], though this population appears to be at equal, or even higher,
risk of insulin-associated weight gain and its subsequent consequences.
Aswith glycemic efficacy, it is important to consider howweight loss
may differ in RCTs versus real-world settings. Evidence suggests that
weight loss from GLP-1 RAs in real-world populations is similar to that
observed in RCTs, although adherence is critical in this regard. In a re-
cent study by Carls et al. [25], patients who were adherent to GLP-1
RA therapy experienced significantly greater weight loss (4.30 kg)
than poorly-adherent patients (1.88 kg).
2.4.2. Hypoglycemia
Insulin and sulfonylureas place patients at considerable risk of hypo-
glycemia. In contrast to exogenous insulin (and insulin secretagogues),
GLP-1 RAs increase endogenous insulin in a glucose-dependent manner.
As a result, risk of hypoglycemia is lowwith GLP-1 RAs, although by low-
ering HbA1c, they amplify the hypoglycemic potential of insulin and sul-
fonylureas [5]. In the Dual Action of Liraglutide and Insulin Degludec in
Type 2 Diabetes (DUAL) II trial [26], 413 patients on basal insulin andmetformin (±sulfonylurea or glinides) were randomized to once-daily
insulin degludec/liraglutide+metformin or once-daily degludec+met-
formin in a blinded fashion. Doses of combination insulin degludec/
liraglutide and degludec alonewere up-titrated according to a predefined
algorithm (target fasting glucose 72-90 mg/dL), and after 26 weeks the
mean daily doses of degludec, alone or as part of combined insulin
degludec/liraglutide, were the same in both arms (45 units, p = NS). In-
terestingly, the incidence of hypoglycemia was comparable between the
treatment arms (insulin degludec/liraglutide 24% versus degludec 25%)
despite a significantly lower mean HbA1c in the insulin degludec/
liraglutide arm [26]. Therefore, the equivalent glucose-lowering action
of GLP-1 RAs coupled with an overall lower risk of hypoglycemia render
them desirable alternatives to insulin. There is no significant difference
in the risk of hypoglycemia across GLP-1 RAs [7].
While priorities regarding weight management may vary on a case-
by-case basis, minimizing hypoglycemia should always be a priority for
patients and providers. Individuals at especially high-risk of hypoglycemia
include elderly patients, those with hypoglycemic unawareness and/or
impaired renal function [27]. Furthermore, avoidance of hypoglycemia is
of utmost importance for individuals in high-risk occupations, such as
truck drivers, pilots, safety officers (police, firefighters), and anyone oper-
ating heavymachinery atwork. In such cases it is preferable to exhaust all
(feasible) glucose-lowering options with low hypoglycemic potential
prior to advancing to sulfonylureas or insulin therapy. In order to mini-
mize hypoglycemia while not compromising glycemic control, GLP-1
RAs could also be considered in those who are fasting for long stretches
of time, such as occurs annually for patients observing Ramadan [28].
2.4.3. Cardiovascular outcomes trials
Amajor update to the ADA-EASD consensus guidelines is the recom-
mendation to consider a history of atherosclerotic cardiovascular dis-
ease, heart failure or chronic kidney disease when deciding on
preferred approaches to glucose-lowering therapy [3]. This is based on
new evidence suggesting that sodium-glucose cotransporter 2
(SGLT2) inhibitors and GLP-1 RAs improve cardiovascular outcomes in
patients with pre-existing cardiovascular disease (CVD) [3,29]. As
discussed by Rizzo et al. in this issue, except for lixisenatide the GLP-1
RAs have demonstrated broad-based benefits on atherosclerotic cardio-
vascular disease outcomes and/or mortality in patients with pre-
existing CVD. Until recently, dulaglutide was the only marketed GLP-1
RA without cardiovascular outcomes data. However, the Researching
cardiovascular Events with a Weekly INcretin in Diabetes (REWIND)
trial results were released in June 2019 [30], and dulaglutide was
found to reduce cardiovascular events compared to placebo; driven pri-
marily by reduction in non-fatal stroke. In contrast to previous cardio-
vascular outcomes trials of GLP-1 RAs, REWIND had the lowest
proportion of participants with pre-existing CVD (31%), the lowest
baseline HbA1c (7.3%), the highest female representation (46%) and
the longestmedian follow-up time (5.4 years) [29,30]. The large propor-
tion of patients without established CVD in REWIND suggests a poten-
tial role for GLP-1 RAs in primary prevention of CVD in those with
diabetes and cardiovascular risk factors (at least two of: tobacco
abuse, dyslipidemia, hypertension or abdominal adiposity) [30]. Addi-
tionally, as the REWIND trial had no lower limit for HbA1c as an eligibil-
ity criterion, and as there was no evidence of heterogeneity based on
HbA1c at entry, this suggests that guidelines regarding cardiovascular
protectionmay need to be generalized to adding dulaglutide, or another
GLP-1 RA with proven efficacy for CV event reduction, independent of
whether the patient is at glycemic goal [30].
Notably, results from the phase 3a Peptide Innovation for Early Dia-
betes Treatment 6 (PIONEER 6) trial were also released in June 2019
[31], and the primary objective of confirming noninferiority of oral
semaglutide to placebo for cardiovascular safety was achieved. Further-
more, a significant relative reduction in risk of cardiovascular death and
all-cause mortality were observed with oral semaglutide compared to
placebo [31].
While insulins are safe to use in patients with pre-existing CVD they
lack evidence for cardiovascular benefit [32,33]; thus GLP-1 RAs should
be preferred in this scenario [3]. If insulin is necessary to achieve glyce-
mic control in patients with CVD, ensuring room for a GLP-1 RA in the
regimen is still desirable for cardiovascular benefit [34]. It remains un-
clear whether cardiovascular protection is a drug-class effect or
whether differences among GLP-1 RAs account for differential effects
on CVD in trials. This should be discussed with patients when deciding
on intensification to GLP-1 RA therapy, as the evidence for cardiovascu-
lar benefit in patients with established CVD is variable and there are
other domains that could drive decision-making in selecting an agent
from within the class.
GLP-1 RAs have also demonstrated reductions in the relative risk of
composite renal outcomes compared to placebo; this effect is primarily
driven by reduction in macroalbuminuria [29,30]. Further studies will
be needed to better understand this potential benefit of GLP-1 RAs, al-
though evidence suggests these agents are at least safe to use from a
renal perspective.
2.4.4. Administration of injectable therapies
Adherence and persistence to therapies are largely influenced by
ease of medication delivery, frequency of dosing, and other aspects of
administration which may add complexity to the daily routine [35,36].
For instance, non-adherence is greater with injectables than pills,
since injectables are more challenging to administer and can be un-
pleasant for the patient. [37] Likewise, adherence is better for insulin
pens than insulin administered by vial and syringe [36,38]. Hence,
when comparing ease of use between medication classes, differences
will be wider between GLP-1 RAs and insulin administered by vial and
syringe, versus GLP-1 RAs and insulin delivered via pen; the latter com-
parison is most commonly assessed in RCTs.
Currently GLP-1 RAs are available in pen form, however delivery sys-
tems vary in complexity. For instance, the initial extended-release
exenatide pen was considerably more complex to use than other GLP-
1 RAs as it required reconstitution, which relied on the patient firmly
tapping the pen on their palm 80 ormore times prior to use. In contrast,
liraglutide and semaglutide employmultiuse penswhich simply require
the patient to dial to the correct dose, remove the needle cap and inject
the medication. The difference in complexity between these two deliv-
ery systems may have accounted for the better adherence observed
with liraglutide versus exenatide in real-world settings [4]. In the U.S.,
a simpler single-use autoinjector device for extended-release exenatide
was developed and became available in 2018; it still requires 15 s of re-
constitution, but is otherwise much easier to use. Dulaglutide is admin-
istered onceweekly as a single use pen and only requires removal of the
needle cap and unlocking of the device before administration. Doses are
preset in the exenatide autoinjector and dulaglutide pens, thus no dose
adjustments are needed. Furthermore, these two devices are the only
ones to hide the needle tip, which may be important for patients
whose fear of needles poses a barrier to adherence.
Efficacy of glucose-lowering agents relies heavily on adherence,
which is inversely related to number of daily injections [39]. With the
exception of twice-daily exenatide, all other GLP-1 RAs allow for the
same or lower number of injections compared to basal insulin (typically
once daily). Extended-release exenatide, dulaglutide and semaglutide
are given weekly, which improves adherence in real-world settings
compared to daily injections, and also aligns more closely with patient
preferences for a once-weekly, single use pen (exenatide, dulaglutide),
versus a daily multiuse pen [4].
Finally, initiation of insulin calls for considerable change to self-
efficacy behaviors, such as consistency in meal taking or carbohydrate
counting, and it requires regular self-monitoring of blood glucose for in-
sulin titration and screening for hypoglycemia. The burden of glucose
self-monitoring can contribute substantially to diabetes distress in pa-
tients initiating insulin. [40] Despite their contribution to non-
adherence [41], patient-reported outcomes such as distress anddepression are often not measured in trials. Since GLP-1 RAs carry min-
imal risk of hypoglycemia, patients do not need to monitor glucose ex-
ceptwhen co-administeredwith an agentwith hypoglycemic potential.
As such, choosing GLP-1 RAs as first injectable therapy relieves patients
of a large self-management burden which may have otherwise contrib-
uted to non-adherence and patient disengagement. In the absence of
background medications that can cause hypoglycemia, GLP-1 RAs are
also easier to prescribe from a provider perspective since they can be
safely started without the need for glycemic trends data.
Real-world persistence to GLP-1 RAs varies by study, but is in the
range of 47% to 80%, and tends to be higher for dulaglutide than for
exenatide or liraglutide [4,42]. While adherence and persistence levels
under 80% may be discouraging for providers, this should not argue
against prescribing GLP-1 RAs, since adherence to insulin also varies
widely, from 43% to 86% [38]. Therefore, focus should instead be placed
on individual patient factors that may influence the selection of one in-
jectable over another, aswell as patient counseling and shared decision-
making to promote adherence.
2.4.5. Safety and tolerability
Gastrointestinal symptoms are the most common side effects of
GLP-1 RA therapy, and occur in as many as 50% of patients [7,43].
They are also the leading cause of GLP-1 RA discontinuation [42].
Among commonly used GLP-1 RAs, semaglutide has the highest rates
of nausea and vomiting, followed by dulaglutide, liraglutide, exenatide
twice-daily, and extended-release exenatide. This pattern is similar for
diarrhea, though liraglutide is slightly more likely to cause diarrhea
than dulaglutide, and both formulations of exenatide are least likely to
do this [7,44,45]. Interestingly, in the DUAL II trial [26] comparing com-
bination insulin degludec/liraglutide versus insulin degludec alone, pa-
tients were blinded and gastrointestinal adverse events were strikingly
lower with combined insulin degludec/liraglutide than reported with
GLP-1 RAs in other trials [46], which was attributed to starting at low
doses with slow up-titrations. Given the high likelihood of gastrointes-
tinal symptoms, it is important to include this in discussions with the
patient prior to initiation. Providers should also initiate GLP-1 RAs at
lowest doses first and ensure that titration beyond maximum tolerated
dose does not occur, or that decreasing to a lower tolerable dose be ac-
complished immediately.
Patientswho experience injection site reactions are also highly likely
to discontinue drug therapy [5]. Overall these reactions are uncommon
with GLP-1 RAs, but not as low as the ≤0.1% incidence with insulin ana-
logues [47]. Extended-release exenatide has the highest risk of injection
site reactions [7], and in the SUSTAIN 3 trial, this occurred in 22% of par-
ticipants, versus 1.2% with semaglutide [45].
From a safety standpoint, a major advantage to GLP-1 RAs over insu-
lin is reduced risk of hypoglycemia, as previously discussed. However,
safety concerns have been raised regarding risk of medullary thyroid
cancer, as well as pancreatic and gallbladder events. Overall, GLP-1RA
increase serum levels of lipase and amylase though this seemsunrelated
to the risk of pancreatitis [48]. In blinded long-term cardiovascular out-
come trials, no significant differences were seen in pancreatitis, pancre-
atic cancer, or medullary thyroid cancer between GLP-1 RA and placebo
[49]. However, evidence suggests that GLP-1 RAs do increase risk of cho-
lelithiasis [48,50,51], though this does not translate to increase in
gallstone-associated acute pancreatitis. Thus, based on recent evidence,
the consensus is that while GLP-1 RAs may increase risk of gallbladder
events, they do not appear to elevate risk of pancreatitis, pancreatic can-
cer, or medullary thyroid cancer, at least in the intermediate-term
follow-up of the trials (b5 years) [48–51].
A final safety consideration worth noting is the higher risk of reti-
nopathy complications observed with semaglutide in the SUSTAIN 6
trial [52]. This occurred predominantly in patients with rapid improve-
ment in glycemic control during the study, a recognized phenomenon of
medication intensification, and one that was even observed with use of
insulin in the Diabetes Control and Complications Trial (DCCT) [53]. As
such, the significance of this finding as it pertains to theGLP-1 RA versus
insulin comparison is unclear, and long-term studies on retinopathy
outcomes are needed to shed further light on this.
2.4.6. Cost considerations
Cost has presented perhaps the greatest limitation to widespread
use of GLP-1 RAs. Cost-effectiveness studies incorporate cost of medica-
tions, as well as other healthcare-related expenditures and quality of
life. Such studies suggest that medication costs associated with GLP-1
RAs are offset by reduction in other healthcare-related expenses, ren-
dering them cost-effective [4,54]. Notably, GLP-1 RAs also negate the
need for glucose self-monitoring, whereas insulin will always be associ-
ated with this added expense. Despite cost-effectiveness to healthcare
systems, many patients are unable to afford GLP-1 RAs.When comparing
patient-level costs, it is important to consider that GLP-1 RAs can replace
50–80 units of insulin with similar glycemic efficacy [10,55]. This daily
cost of insulin is not trivial, particularly for insulin analogues whose
cost has risen dramatically over the past several years [56–58]. Therefore,
for patients with an average HbA1c of 8–8.5% (as in RCTs), cost parity is
arguably similar between GLP-1 RA and insulin analogues in many
cases; though data are mixed [59,60]. Human insulins are cheaper and
should compare favorably with respect to the cost of GLP-1 RAs, though
direct comparisons in trials have not been performed.
3. Conclusion
Recent guidelines recommend GLP-1 RAs as initial injectable ther-
apy over basal insulin inmost cases, based on similar or higher glycemic
efficacy, weight reduction, lower risk of hypoglycemia, and cardiovascu-
lar benefit in those with atherosclerotic CVD. Real-world evidence sug-
gests that adherence is suboptimal for both GLP-1 RAs and insulin, the
former driven by adverse gastrointestinal symptomswhich are common.
Assuming adherence, GLP-1 RAs offer numerous benefits beyond insulin
which have been discussed in this review, including lower self-
management burden and the possibility of fewer injections. However
with this shift in recommendations it is important for providers to engage
patients in care discussions and to bemindful of individual factors which
may impact the success of therapy, such as safety, tolerability and cost.
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